
Study Results Keynote-426 A study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma

source : ASCO GU 2019, https://meetinglibrary.asco.org/record/170343/abstract






Trial Design


Objective **Response Rate** (ORR)

in the whole trial population (regardless of IMDC categories)





% of Patients with Partial or Complete Response



IKCC nternational Kidney Cancer Coalition * Including Grade 5 (death related to treatment) for 0.9% and 1.6% respectively)

© IKCC = International Kidney Cancer Coalition, www.ikcc.org, www.10forio.info

